| |
|
|
 |
 |
|
|
 |
|
|
| |
ACCELERATED
TECHNOLOGIES is a unique
partnership model for the
creation and acceleration of
cardiovascular devices into
the market. Market needs
are identified by the
company's team of
physicians and are then
translated into products.
|
| |
|
|
|
|
|
|
 |
|
|
| |
BIOLINERX is a bio-
pharmaceutical drug
development company
that in-licenses compounds
primarily from Israeli
academia and hospitals and
takes these molecules to
a higher valuation in future
royalty streams by filling the
gap in the developmental
phase. |
| |
|
|
|
|
|
|
 |
|
|
| |
|
| |
CAN-FITE focuses on drugs
for treating cancer and
inflammatory diseases
providing drugs that are
highly efficacious in their
therapeutic activity but
devoid of some of the major
shortcomings inherent in
many of the drug therapies
currently available. |
| |
|
|
|
|
|
|
|
 |
|
|
| |
|
CircuLite focuses on the
treatment of advanced heart
failure patients who cannot
pump enough blood to meet the
body’s metabolic needs.
The Circulite microvad system’s
pump is designed to solve the
problems of mechanical failure and
blood clotting exhibited in
artificial hearts and pumps.
|
| |
|
|
|
|
|
|
 |
|
|
| |
COMPUGEN, a drug and
diagnostic discovery company,
incorporates ideas and
methods from mathematics,
computer science and physics
into the disciplines of biology,
organic chemistry and
medicine increasing the success of drug and diagnostic development.
Compugen went public on
NASDAQ in August 2000. |
| |
|
|
|
|
|
|
 |
|
|
| |
GLUCON develops devices
which provide non-invasive,
continuous, accurate, and
real-time blood glucose
monitoring for clinical and
personal use. |
| |
|
|
|
|
|
|
 |
|
|
| |
Impella is an innovative
high-tech enterprise which
manufactures and markets
intracorporeal micro blood
pumps for use in coronary
surgery and cardiology.
Abiomed acquired Impella for $92 million in May 2005. |
| |
|
|
|
|
|
|
 |
|
|
| |
| Mitralign designs and develops percutaneous transcatheter devices for the treatment of mitral valve regurgitation which is a significant factor in congestive heart failure. |
| |
|
|
|
|
|
|
 |
|
|
| |
ORIDION is an innovator in
the areas of respiratory
patient monitoring systems
and breath testing analyzers.
Oridion went public on
the Swiss SWX New
Market Exchange in April
2000. |
| |
|
|
|
|
|
|
 |
|
|
| |
| Pathway Medical develops and manufactures an innovative catheter based technology to treat peripheral vascular disease. |
| |
|
|
|
|
|
|
 |
|
|
| |
PRONEURON focuses on cell
therapy and neuroimmunology
on the development and
commercialization of
treatments for spinal cord
injuries (SCI) as well as other
neurological disorders. |
| |
|
|
|
|
|
|
 |
|
|
| |
PROTEOLOGICS develops a
class of drugs for viral and
other ubiquitin-mediated
diseases utilizing unique
technology and knowledge
of the ubiquitin system. |
| |
|
|
|
|
|
|
 |
|
|
| |
TOPSPIN has developed a
unique technology for local
high-resolution MR imaging
using a miniature hand-held
probe incorporating all
magnetic field sources and
eliminating the need for
external magnets and a
bulky and expensive MRI
scanner. |
| |
|
|
|
|
|
|
 |
|
|
| |
ULTRASPECT develops
products for medical imaging
based on novel image-
processing algorithms. |
| |
|
|
|
|
|
|
 |
|
|
| |
| X-Cell Medical is a development stage biotech company committed to the discovery and development of novel therapeutic products for cardiovascular diseases. |
| |
|
|
|
|
|
|
 |
|
|
| |
X TECHNOLOGIES developed
a revolutionary balloon
angioplasty device designed
to address several pressing
needs in the coronary
angioplasty and stenting
market.
Acquired by Guidant in
March 2003. |
| |
|
|
|
|
|
|
|
|
| |
